The Journey to Optimizing Outcomes: Advances in Drug Delivery & Design

THURSDAY, March 12, 2015 • 08:30 — 16:30

Pfizer, Inc., 610 Main St., Cambridge, MA


The Catalent Institute and noteworthy drug delivery experts from Catalent Pharma Solutions, Pfizer Inc., Liquidia Technologies, Dispersol, Rutgers University and Cloud Pharmaceuticals presented Advances in Drug Delivery & Design: The Patient Journey and Addressing Solubility & Bioavailability Challenges for Improved Outcomes. This event was designed to cater to Vice Presidents, Directors, Principal Scientists and Graduate Students joining us from leading pharmaceutical companies and universities.

The expert panel, led by the Catalent Institute Board Members, focused on providing solutions for drug development challenges facing every R&D team today.  Participants were encouraged to bring their toughest challenges in order to get the most from the sessions.


8:30 AM – 9:00 AM | Registration and Breakfast

9:00 AM – 9:30 AM | Welcome & Introduction

  • Hot Topics, the Drug Delivery Challenge Framework – State, Rate & Location

9:30 AM – 10:30 AM | The Patient Journey: Insights to Optimized Drug Delivery

  •  Partnering to Identify Hurdles in Compliance., Adherence & Patient Experience

10:30 AM – 10:45 AM | Break

10:45 AM – 11:30 AM | Lipid Based Solutions

  • “Accelerating the development of compounds with bioavailability limitations” – A Case Study

11:30 AM – 12:00 PM | Innovation in Solubility Enhancement

  • “Recent Advances in Amorphous Dispersion Technologies”

11:45 AM – 12:15 PM | OSDrC®OptiDoseTM Case Study

  • Achieving Novel Drug Delivery Profiles for Pain Therapeutics (Delayed Release)

12:00 PM – 12:30 PM | Q&A from Morning Sessions

12:30 PM – 1:30 PM | Networking Lunch and Meet the Experts

1:30 PM – 2:00 PM | Interesting Trends in Drug Delivery 

2:00 PM – 3:00 PM | Nanotechnology

  • Landscape and application of nanotechnology in drug delivery – Case studies

3:00 PM – 3:15 PM | Break

3:15 PM – 3:45 PM | Data driven drug design – in silico optimization of BBB permeability and toxicity for better drugs      

3:45 PM – 4:15 PM | Is Predictive Selection of Preferred Drug Delivery Technology a Myth or Reality?

4:15 PM – 4:30 PM | Closing remarks



Terry Robinson

Executive Director, Catalent Institute

Ms. Robinson has over 25 years of experience in pharmaceutical strategy, development and program management. Her expertise includes bringing business and technical leaders together to create shared vision and achieve mutual objectives. Prior to her current role, Ms. Robinson was Executive Director of Global Accounts responsible for Catalent’s largest strategic customers and was named Executive Director of the Catalent Applied Drug Delivery Institute as of February 2013. Ms. Robinson holds a Bachelor’s degree in Psychobiology as well as a Certificate in Aging Studies from The University of Virginia.


Dr. Cornell Stamoran

Ph.D., Catalent Institute Board Member, Vice President, Strategy & Corporate Development, Catalent Pharma Solutions

Dr. Stamoran has spent nearly 25 years engaged with the healthcare industry, and has experienced the realities of patient adherence and outcomes enhancement from almost every stakeholder perspective: from direct engagement with retail and hospital pharmacists; medical professionals; specialty pharmacies and clinics; and pharmacy benefit managers and payers. He has directly participated in adherence and outcomes enhancement strategies for more than 150 drugs over the last 10 years.

Stephen Tindal

Stephen Tindal

Director, Softgel R&D, Catalent Pharma Solutions

Stephen holds a bachelor’s degree in Chemistry and Analytical Science from Loughborough University, UK.  He has worked in softgel R&D for 27 years and has broad expertise in the technology.  Stephen specializes in root cause investigation, technology innovation, gelatin innovation, customer liaison and supporting business development.  Stephen is part of Catalent’s R&D Team at the Company Headquarters in Somerset, New Jersey.

 Dave Miller

Dr. Dave Miller

Vice President of Research and Development,
DisperSol Technologies

Dave A. Miller, Ph.D. is the Vice President of Research and Development at DisperSol Technologies. He earned a B.S. in Chemical Engineering and a Ph.D. in Pharmaceutics from the University of Texas at Austin. Prior to joining DisperSol, Dr. Miller held the position of Senior Principal Scientist at Hoffmann-La Roche, Inc. Dr. Miller has published numerous research articles, book chapters, and patent applications in the field of solubility enhancement and is co-editor of the recently published book, Formulating Poorly Water Soluble Drugs. 


Ronald Vladyka

Director, Formulation Research and Development Advance Delivery Technologies, Catalent Pharma Solutions

Ron Vladyka has over 20 years of experience in pharmaceutical development.  His development experience, over his career, has included development of novel delivery systems for parental, inhalation, and oral administration.  Ron has been part of the formulation development team at Catalent for over six years.  His responsibilities include development and transfer of technologies and oral delivery systems that aid in solubilizing poorly soluble drugs compounds.  His other research interests include compaction and multi-particulate modified release systems.  He also holds several U.S. Patents in the area of improvement of bioavailability.


Dr. Benjamin Maynor

Ph.D., VP R&D, Liquidia Technologies

Benjamin Maynor, Ph.D. is currently serves as the Vice President, Research at Liquidia Technologies, a nanotechnology company in the Research Triangle Park, NC that focuses on the production of drug delivery systems for ophthalmology, vaccines, and pulmonary therapeutics. As part of his responsibilities he also leads Liquidia’s programs for small molecule/biologic drug delivery. Ben is a co-inventor of Liquidia’s PRINT technology. He joined Liquidia in 2005 and has initiated several new technology initiatives at Liquidia, including programs in ophthalmology, respiratory drug delivery, and other therapeutic areas. He received a Ph.D. in Chemistry from Duke University, where he focused on nanofabrication, nanostructure synthesis and materials chemistry. He also holds a B.A. in Chemistry from Harvard University. He has co-authored over 20 peer-reviewed publications in the fields of nanotechnology, colloid science, and drug delivery and has been a co-inventor on several patents and patent applications in the fields of nanotechnology and drug delivery.

Ronak Savla

Dr. Ronak Savla

Applied Drug Delivery Fellow,
Rutgers Pharmaceutical Industry Fellowship Program

Ronak Savla is currently the Applied Drug Delivery Fellow with Catalent Pharma Solutions through the Rutgers Pharmaceutical Industry Fellowship Program. Ronak graduated summa cum laude with a Doctor of Pharmacy degree from Rutgers School of Pharmacy and a Ph.D. in Pharmaceutical Sciences from Rutgers University. Ronak has experience working with tumor responsive targeted multifunctional nanosystems for cancer imaging, chemo- and siRNA therapy. Ronak is an author and co-author on over 35 publications including peer-reviewed papers, conference proceedings, and posters.


Dr. Shahar Keinan

Chief Scientific Officer, Cloud Pharmaceuticals

Shahar Keinan has extensive experience in the field of computational and theoretical chemistry. She obtained a Ph.D. in theoretical chemistry and a B.S. in Chemistry from The Hebrew University of Jerusalem, and post-doc in Northwestern and Duke universities. She has published over 25 peer-reviewed research articles.


Ravi Shanker

Senior Research Fellow, department of Drug Product Design of Pharmaceutical Sciences, Pfizer, Inc.

Ravi Shanker is Senior Research Fellow in the department of Drug Product Design of Pharmaceutical Sciences at Pfizer Worldwide Research and Development in Groton CT. Ravi has over 25 years of research experience in the areas of drug delivery, discovery support and biopharmaceutics at Pfizer. He has numerous papers and patents in the field of drug delivery. Ravi has mentored PhD dissertation research for students and taught graduate level courses as an adjunct faculty member. He has collaborated globally with industrial entrepreneurs and academic researchers for enhanced fundamental understanding of drug absorption and delivery. He has been an invited speaker at numerous national and international conferences and is a member of the Editorial Board of Journal of Pharmaceutical Science. Ravi’s current responsibilities include leading a global Biopharmaceutics Group at Pfizer. Ravi received his Bachelors in Pharmacy from Banaras Hindu University in India; Masters and PhD in Pharmaceutical Chemistry from the University of Kansas.


Chris Evans

Senior Director, Innovation, West Pharmaceutical Services

Chris has been in new product development for over 25 years, primarily in pharmaceutical & healthcare packaging/device development. His background is in Engineering and Industrial Design, and he holds 19 U.S. patents with a dozen more pending. Chris is responsible for West’s user-centered delivery device design, with a focus on early stage innovation, technology integration, platform feasibility and optimizing the patient experience.